NCT00227370View on ClinicalTrials.gov

Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation

PHASE3CompletedINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

April 30, 2008

Study Completion Date

December 31, 2008

Conditions

Cytomegalovirus Infections

Interventions

DRUG

valganciclovir

valgan 900mg QD x 9 months post lung transplant

OTHER

Placebo

Trial Locations (1)

27710

DukeUMC, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

collaborator

Roche Pharma AG

INDUSTRY

lead

Duke University

OTHER

NCT00227370 - Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation | Biotech Hunter | Biotech Hunter